Search
Upstream Bio Inc
UPBAdd to Watchlist
6.250USD
+0.100+1.63%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
340.12MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Upstream Bio Inc is 7.78, ranking 275 out of 389 in the Biotechnology & Medical Research industry. The average price target is 43.00, with a high of 75.00 and a low of 35.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
43.500
Target Price
+607.32%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Upstream Bio Inc
UPB
9
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Upstream Bio Inc's expected revenue for the next quarter?
Upstream Bio Inc's expected revenue is 430.71K.
What is Upstream Bio Inc's price target?
Analysts forecast that Upstream Bio Inc's price target is USD 43.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 35.00.
How have Upstream Bio IncUPB's recent earnings per share performed?
The market expectation was USD -0.75, while Upstream Bio IncUPB's earnings per share (EPS) for the previous quarter was USD -2.66. EPS for the next quarter is expected at USD -0.76.
What is the analyst rating for Upstream Bio Inc?
Based on the ratings of Upstream Bio Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
